期刊文献+

放化疗联合脑转移瘤放疗治疗非小细胞肺癌脑转移的临床疗效分析 被引量:3

Analysis of clinical effect by chemoradiotherapy combined with metastatic encephaloma radiotherapy in the treatment of non-small cell lung cancer with brain metastases
下载PDF
导出
摘要 目的探讨放化疗联合脑转移瘤放疗治疗非小细胞肺癌脑转移的临床疗效。方法选取43例非小细胞肺癌脑转移的患者作为研究对象,给予患者放化疗联合脑转移瘤放疗治疗,观察患者的生存情况及临床治疗效果。结果 43例患者经过相应的临床治疗后,1年存活率为69.8%(30/43),2年存活率为46.5%(20/43),3年存活率为25.6%(11/43)。结论采用放化疗联合脑转移瘤放疗治疗非小细胞肺癌脑转移的临床疗效显著,值得临床推广使用。 Objective To investigate clinical effect by chemoradiotherapy combined with metastatic encephaloma radiotherapy in the treatment of non-small cell lung cancer with brain metastases. Methods A total of 43 non-small cell lung cancer with brain metastases patients as study subjects all received chemoradiotherapy combined with metastatic encephaloma radiotherapy. Observation was made on survival situation and clinical effect in patients. Results After clinical treatment in 43 patients, they had 1-year survival rate as 69.8%(30/43), 2-year survival rate as 46.5%(20/43)and 3-year survival rate as 25.6%(11/43). Conclusion Implement of chemoradiotherapy combined with metastatic encephaloma radiotherapy shows excellent clinical effect in treating non-small cell lung cancer with brain metastases, and this method is worth clinical promotion and application.
出处 《中国实用医药》 2016年第33期134-135,共2页 China Practical Medicine
关键词 放化疗 脑转移瘤放疗治疗 非小细胞肺癌 脑转移 临床疗效 Chemoradiotherapy Metastatic encephaloma radiotherapy Non-small cell lung cancer Brain metastases Clinical effect
  • 相关文献

参考文献11

二级参考文献129

  • 1田军,施瑞浩,江涛,曾昭冲,张新,白春学.45例肺癌脑转移放射治疗后生存期的影响因素[J].中国癌症杂志,2006,16(4):310-312. 被引量:12
  • 2吴梅娜,刘叙仪,方健,安彤同,王洁.111例非小细胞肺癌脑转移的治疗与预后[J].中国肺癌杂志,2006,9(6):540-543. 被引量:8
  • 3齐彩霞,安永恒.化疗药物透过血脑屏障的研究进展评价[J].中国医院用药评价与分析,2007,7(1):31-34. 被引量:10
  • 4Robinet G, Thomas P, Breton JL, et al. Results of a phase Ⅲ study of early versus delayed whole brain radiotherapy with concurrent cisplatin vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol, 2001, 12(1): 59-67.
  • 5Kim JH, Kim HS, Kwon JH, et al. Systemic chemotherapy after cranial irradiation in patients with brain metastases from non-small cell lung cancer: a retrospective study. Lung Cancer, 2009, 63(3): 405-409.
  • 6Lee DH, Han JY, Kim HT, et al. Primary chemotherapy for newly diagnosed non small cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first: result of a randomized pilot study. Cancer, 2008, 113 (1): 143-149.
  • 7Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage Ⅲ B or Ⅳ non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol, 2003, 21: 2933-2939.
  • 8Grossi F, Belvedere O, Fasola G, et al. Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced on-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001). Lung Cancer, 2004, 46(1): 99-106.
  • 9Lee JS, Ignacio J, Yu C, et al. FAST-ACT: A phase Ⅱ randomized double- blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage Ⅲ B/Ⅳ non-small cell lung cancer (NSCLC). J Clin Oncol, 2008, 26(Suppl): abstr 8031.
  • 10Ciuleanu TE, Brodowicz T, Belani CP, et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase Ⅲ study: J Clin Oncol, 2008, 26(Suppl): abstr 8011.

共引文献177

同被引文献21

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部